PortalPublikationenPlacebo cohorts in phase-3 MS treatment trials - predictors ...

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.

Standard

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. / Stellmann, Jan-Patrick; Neuhaus, Anneke; Herich, Lena; Schippling, Sven; Roeckel, Matthias; Daumer, Martin; Martin, Roland; Heesen, Christoph.

in: PLOS ONE, Jahrgang 7, Nr. 11, 11, 2012, S. 50347.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stellmann, J-P, Neuhaus, A, Herich, L, Schippling, S, Roeckel, M, Daumer, M, Martin, R & Heesen, C 2012, 'Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.', PLOS ONE, Jg. 7, Nr. 11, 11, S. 50347. https://doi.org/10.1371/journal.pone.0050347

APA

Stellmann, J-P., Neuhaus, A., Herich, L., Schippling, S., Roeckel, M., Daumer, M., Martin, R., & Heesen, C. (2012). Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLOS ONE, 7(11), 50347. [11]. https://doi.org/10.1371/journal.pone.0050347

Vancouver

Stellmann J-P, Neuhaus A, Herich L, Schippling S, Roeckel M, Daumer M et al. Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLOS ONE. 2012;7(11):50347. 11. https://doi.org/10.1371/journal.pone.0050347

Bibtex

@article{cd80b78b8b5f432ca6609678f4d4fa07,
title = "Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.",
abstract = "Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled trials (RCT) of new treatments for relapsing remitting multiple sclerosis (RRMS) have decreased substantially during the last two decades. The causes of these changes are not clear. We consider a better understanding of this phenomenon essential for valuing the effects of new drugs and by designing new trials.",
keywords = "Humans, Male, Female, Randomized Controlled Trials as Topic, Cohort Studies, Regression Analysis, Time Factors, Research Design, Recurrence, Outcome Assessment (Health Care), Poisson Distribution, Models, Statistical, Clinical Trials, Phase III as Topic, Multiple Sclerosis, Relapsing-Remitting/*therapy, *Placebos, Humans, Male, Female, Randomized Controlled Trials as Topic, Cohort Studies, Regression Analysis, Time Factors, Research Design, Recurrence, Outcome Assessment (Health Care), Poisson Distribution, Models, Statistical, Clinical Trials, Phase III as Topic, Multiple Sclerosis, Relapsing-Remitting/*therapy, *Placebos",
author = "Jan-Patrick Stellmann and Anneke Neuhaus and Lena Herich and Sven Schippling and Matthias Roeckel and Martin Daumer and Roland Martin and Christoph Heesen",
year = "2012",
doi = "10.1371/journal.pone.0050347",
language = "English",
volume = "7",
pages = "50347",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

RIS

TY - JOUR

T1 - Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.

AU - Stellmann, Jan-Patrick

AU - Neuhaus, Anneke

AU - Herich, Lena

AU - Schippling, Sven

AU - Roeckel, Matthias

AU - Daumer, Martin

AU - Martin, Roland

AU - Heesen, Christoph

PY - 2012

Y1 - 2012

N2 - Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled trials (RCT) of new treatments for relapsing remitting multiple sclerosis (RRMS) have decreased substantially during the last two decades. The causes of these changes are not clear. We consider a better understanding of this phenomenon essential for valuing the effects of new drugs and by designing new trials.

AB - Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled trials (RCT) of new treatments for relapsing remitting multiple sclerosis (RRMS) have decreased substantially during the last two decades. The causes of these changes are not clear. We consider a better understanding of this phenomenon essential for valuing the effects of new drugs and by designing new trials.

KW - Humans

KW - Male

KW - Female

KW - Randomized Controlled Trials as Topic

KW - Cohort Studies

KW - Regression Analysis

KW - Time Factors

KW - Research Design

KW - Recurrence

KW - Outcome Assessment (Health Care)

KW - Poisson Distribution

KW - Models, Statistical

KW - Clinical Trials, Phase III as Topic

KW - Multiple Sclerosis, Relapsing-Remitting/therapy

KW - Placebos

KW - Humans

KW - Male

KW - Female

KW - Randomized Controlled Trials as Topic

KW - Cohort Studies

KW - Regression Analysis

KW - Time Factors

KW - Research Design

KW - Recurrence

KW - Outcome Assessment (Health Care)

KW - Poisson Distribution

KW - Models, Statistical

KW - Clinical Trials, Phase III as Topic

KW - Multiple Sclerosis, Relapsing-Remitting/therapy

KW - Placebos

U2 - 10.1371/journal.pone.0050347

DO - 10.1371/journal.pone.0050347

M3 - SCORING: Journal article

VL - 7

SP - 50347

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 11

M1 - 11

ER -